Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, <i>EGFR</i> Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.

Girard N, Goldman J, Lu S, Bar J, Horinouchi H, Daaboul N, Liu C, Çiçin I, Katgi N, Zer A, Ciuleanu T, Reinmuth N, Planchard D, Lee SH, Mansfield AS, Moskovitz M, Baijal S, Baik C, Hrom JS, Heist RS, Yazici O, Verma M, Uema D, Patel S, Xia S, Ratajczak C, Camidge DR.

Open source

DOI: 10.1016/j.jtocrr.2026.100988
Published: 2026-03-16
Container: JTO Clin Res Rep
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtocrr.2026.100988,
  title = {Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, \&lt;i\&gt;EGFR\&lt;/i\&gt; Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.},
  author = {Girard N and  Goldman J and  Lu S and  Bar J and  Horinouchi H and  Daaboul N and  Liu C and  Çiçin I and  Katgi N and  Zer A and  Ciuleanu T and  Reinmuth N and  Planchard D and  Lee SH and  Mansfield AS and  Moskovitz M and  Baijal S and  Baik C and  Hrom JS and  Heist RS and  Yazici O and  Verma M and  Uema D and  Patel S and  Xia S and  Ratajczak C and  Camidge DR.},
  year = {2026},
  journal = {JTO Clin Res Rep},
  doi = {10.1016/j.jtocrr.2026.100988},
  url = {https://doi.org/10.1016/j.jtocrr.2026.100988}
}

RIS

TY  - JOUR
TI  - Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, &lt;i&gt;EGFR&lt;/i&gt; Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.
AU  - Girard N
AU  -  Goldman J
AU  -  Lu S
AU  -  Bar J
AU  -  Horinouchi H
AU  -  Daaboul N
AU  -  Liu C
AU  -  Çiçin I
AU  -  Katgi N
AU  -  Zer A
AU  -  Ciuleanu T
AU  -  Reinmuth N
AU  -  Planchard D
AU  -  Lee SH
AU  -  Mansfield AS
AU  -  Moskovitz M
AU  -  Baijal S
AU  -  Baik C
AU  -  Hrom JS
AU  -  Heist RS
AU  -  Yazici O
AU  -  Verma M
AU  -  Uema D
AU  -  Patel S
AU  -  Xia S
AU  -  Ratajczak C
AU  -  Camidge DR.
PY  - 2026
JO  - JTO Clin Res Rep
DO  - 10.1016/j.jtocrr.2026.100988
UR  - https://doi.org/10.1016/j.jtocrr.2026.100988
ER  -

APA

N, G., J, G., S, L., J, B., H, H., N, D., C, L., I, Ç., N, K., A, Z., T, C., N, R., D, P., SH, L., AS, M., M, M., S, B., C, B., JS, H., RS, H., O, Y., M, V., D, U., S, P., S, X., C, R., & DR., C. (2026). Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, <i>EGFR</i> Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.. JTO Clin Res Rep. https://doi.org/10.1016/j.jtocrr.2026.100988

Source records

europe-pmc · retrieved 2026-09-26T11:33:03.384Z
doaj · retrieved 2026-09-26T11:33:03.361Z

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, &lt;i&gt;EGFR&lt;/i&gt; Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.

Credibility signals

Cite this work

BibTeX

RIS

APA

Source records

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, <i>EGFR</i> Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.